# Novel Glucose Responsive Insulin for Improved Treatment of Diabetes

> **NIH NIH R43** · AMIDEBIO, LLC · 2022 · $116,045

## Abstract

SUMMARY/ABSTRACT.
Diabetes is rapidly becoming a global health crisis. Depending on the type of statistical methodology used, the
world-wide incidence of the most common type of diabetes, adult-onset or Type II, is estimated to be in the range
of 285 million. In both Type I and Type II diabetics glycemic control is paramount as the inability to maintain
glycemic control results in several secondary complications including neuropathy, nephropathy and retinopathy,
that often lead to amputations, dialysis and blindness as well as increased risk of cardiovascular complications.
For the majority of diabetics glycemic control requires constant vigilance and monitoring of blood glucose levels.
The overarching goal of this project is the development of a novel glucose responsive insulin (GRI) with a
reversible, glucose dependent response at the insulin receptor. The full realization of the GRI concept would
most closely mimic the benefits of a healthy pancreas and maintain euglycemia, reduce/eliminate the need for
constant monitoring, and ultimately, reduce/eliminate the complications of diabetes. The scope of this proposal
is the design and testing of a series of analogs that can bind glucose allosterically and demonstrate differential
response at the insulin receptor. This will be achieved through completion of three aims. In Aim 1 we will use a
novel computational platform to design and produce a series of GRIs with glucose binding affinity in the
physiological range. In Aim 2 we will determine the glucose binding affinity of the analogues produced in Aim 1.
Finally, in Aim 3 we will measure the insulin receptor (IR) and insulin like growth factor (IGF-R1) affinity of the
GRI’s in the presence of glucose at physiological concentrations. Completion of these Aims will result in the
identification of several GRI lead candidates with glucose binding in the physiological range and reversible
glucose dependent insulin receptor binding and absence of IGF-1R binding.

## Key facts

- **NIH application ID:** 10360668
- **Project number:** 5R43DK126521-02
- **Recipient organization:** AMIDEBIO, LLC
- **Principal Investigator:** Pawel Fludzinski
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $116,045
- **Award type:** 5
- **Project period:** 2021-03-01 → 2023-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10360668

## Citation

> US National Institutes of Health, RePORTER application 10360668, Novel Glucose Responsive Insulin for Improved Treatment of Diabetes (5R43DK126521-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10360668. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*